| Literature DB >> 33085933 |
Daneng Li1, Adam Rock2, Jonathan Kessler3, Richard Ballena1, Shadman Hyder1, Christiana Mo4, Sue Chang5, Gagandeep Singh6.
Abstract
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms that arise in the neuroendocrine cells of the pancreas. Although their clinical presentations differ depending on cell type, most are indolent, whereas others cause noteworthy hormone-related symptoms. The increasing incidence of PanNETs, attributed to improved diagnostic modalities, demonstrates advances in current standard of care. However, given the heterogeneity of these tumors, treatment decisions can become complex and an individualized approach is often required. Surgical intervention has remained the mainstay for localized tumors, whereas systemic therapies remain viable options for patients with unresectable or metastatic disease. Liver-directed therapies such as radiofrequency ablation and hepatic arterial embolization have also become available adjunct therapies for patients with liver-predominant metastases. Despite the increase in the armamentarium of treatment options for patients with PanNETs, data regarding the ideal sequence of treatment, especially systemic treatments, are currently lacking. Ongoing clinical trials are aimed at addressing this knowledge gap in addition to developing the next generation of novel therapeutics.Entities:
Mesh:
Year: 2020 PMID: 33085933 DOI: 10.1200/JCOOP.20.00010
Source DB: PubMed Journal: JCO Oncol Pract ISSN: 2688-1527